|
Net benefit of RYR preparations in lipid profile in placebo-controlled trials |
||||||
| No. of subjects |
Baseline |
Post-treatment |
Difference |
P value |
||
|
|
||||||
| Mean (SD) |
Mean (SD) |
Mean (95% CI) |
% Change |
|||
|
|
||||||
| TC levels (mmol/L) |
||||||
| Cholestin |
42 |
6.47 (0.78) |
5.43 (0.80) |
-1.04 (-1.38 to -0.70) |
-16% |
< 0.00001 |
| Placebo |
41 |
6.59 (0.75) |
6.47 (0.93) |
-0.12 (-0.49 to 0.25) |
-2% |
0.52 |
| 30 |
6.68 (0.98) |
5.31 (0.84) |
-1.37 (-1.83 to -0.91) |
-21% |
||
| 33 |
5.81 (0.63) |
4.26 (0.63) |
-1.55 (-1.85 to -1.25) |
-27% |
||
| Xuezhikang |
101 |
7.30 (1.40) |
5.90 (1.40) |
-1.40 (-1.79 to -1.01) |
-19% |
|
| 30 |
5.65 (1.31) |
3.16 (1.31) |
-2.49 (-3.15 to -1.83) |
-44% |
||
| Subtotal: 194 |
-1.63 (-2.00 to -1.26) |
< 0.00001 |
||||
| 28 |
6.72 (0.97) |
6.43 (0.93) |
-0.29 (-0.79 to 0.21) |
-4% |
||
| 30 |
5.84 (0.67) |
4.94 (0.67) |
-0.90 (-1.24 to -0.56) |
-15% |
||
| Placebo |
51 |
6.80 (1.40) |
6.70 (1.40) |
-0.10 (-0.64 to 0.44) |
-1% |
|
| 20 |
5.55 (1.02) |
4.95 (1.02) |
-0.60 (-1.23 to 0.03) |
-11% |
||
| Subtotal: 129 |
-0.50 (-0.90 to -0.11) |
0.01 |
||||
| 9 |
5.90 (0.95) |
4.94 (0.65) |
-0.96 (-1.71 to -0.21) |
-16% |
||
| Zhibituo |
30 |
6.70 (1.10) |
5.80 (0.90) |
-0.90 (-1.41 to -0.39) |
-13% |
|
| 104 |
7.10 (1.70) |
5.60 (1.30) |
-1.50 (-1.91 to -1.09) |
-21% |
||
| Subtotal: 143 |
-1.17 (-1.59 to -0.74) |
< 0.00001 |
||||
| 9 |
5.83 (0.57) |
5.56 (0.53) |
-0.27 (-0.78 to 0.24) |
-5% |
||
| Placebo |
30 |
6.70 (1.50) |
6.40 (1.30) |
-0.30 (-1.01 to 0.41) |
-4% |
|
| 101 |
6.00 (1.80) |
6.50 (0.70) |
0.50 (0.12 to 0.88) |
8% |
||
| Subtotal: 140 |
0.02 (-0.56 to 0.60) |
0.95 |
||||
| TG levels (mmol/L) |
||||||
| Cholestin |
42 |
1.50 (0.54) |
1.40 (0.50) |
-0.10 (-0.32 to 0.12) |
-7% |
0.38 |
| Placebo |
41 |
1.61 (0.52) |
1.65 (0.53) |
0.04 (-0.19 to 0.27) |
2% |
|
| 30 |
2.84 (0.57) |
2.38 (0.62) |
-0.46 (-0.76 to -0.16) |
-16% |
||
| 33 |
2.10 (0.92) |
1.82 (0.92) |
-0.28 (-0.72 to 0.16) |
-13% |
||
| Xuezhikang |
101 |
3.60 (2.40) |
2.30 (1.60) |
-1.30 (-1.86 to -0.74) |
-36% |
|
| 30 |
2.62 (0.58) |
1.47 (0.58) |
-1.15 (-1.44 to -0.86) |
-44% |
||
| Subtotal: 194 |
-0.78 (-1.26 to -0.31) |
0.001 |
||||
| 28 |
2.74 (0.73) |
2.57 (0.69) |
-0.17 (-0.54 to 0.20) |
-6% |
||
| Placebo |
30 |
2.14 (0.94) |
1.91 (0.94) 3.00 (1.60) |
-0.23 (-0.71 to 0.25) -0.30 (-0.92 to 0.32) |
-11% |
|
| 51 |
3.30 (1.60) |
3.00 (1.60) |
-0.30 (-0.92 to 0.32) |
-9% |
||
| 20 |
2.50 (0.50) |
2.11 (0.50) |
-0.39 (-0.70 to -0.08) |
-16% |
||
| Subtotal: 129 |
-0.29 (-0.49 to -0.09) |
0.005 |
||||
| 13 |
2.46 (1.23) |
1.79 (0.57) |
-0.67 (-1.41 to 0.07) |
-27% |
||
| Zhibituo |
30 |
3.40 (0.90) |
2.10 (1.10) |
-1.30 (-1.81 to -0.79) |
-38% |
|
| 104 |
3.40 (1.50) |
2.30 (1.30) |
-1.10 (-1.48 to -0.72) |
-32% |
||
| Subtotal: 147 |
-1.10 (-1.38 to -0.82) |
< 0.00001 |
||||
| 9 |
2.56 (0.88) |
2.36 (0.64) |
-0.20 (-0.91 to 0.51) |
-8% |
||
| 30 |
3.40 (1.10) |
3.10 (1.20) |
-0.30 (-0.88 to 0.28) |
-9% |
||
| Placebo |
101 |
3.10 (0.40) |
2.50 (1.40) |
-0.60 (-0.88 to -0.32) |
-19% |
|
| Subtotal: 140 |
-0.50 (-0.74 to -0.26) |
< 0.0001 |
||||
| LDL-C levels (mmol/L) |
||||||
| Cholestin |
42 |
4.47 (0.70) |
3.49 (0.70) |
-0.98 (-1.28 to -0.68) |
-22% |
< 0.00001 |
| Placebo |
41 |
4.65 (0.78) |
4.53 (0.85) |
-0.12 (-0.47 to 0.23) |
-3% |
0.51 |
| 30 |
3.94 (0.82) |
2.83 (0.88) |
-1.11 (-1.54 to -0.68) |
-28% |
||
| 33 |
4.13 (0.52) |
2.80 (0.52) |
-1.33 (-1.58 to -1.08) |
-32% |
||
| Xuezhikang |
101 |
4.80 (1.60) |
3.50 (1.40) |
-1.30 (-1.71 to -0.89) |
-27% |
|
| 30 |
3.00 (1.03) |
2.10 (1.03) |
-0.90 (-1.42 to -0.38) |
-30% |
||
| Subtotal: 194 |
-1.23 (-1.41 to -1.05) |
<0.00001 |
||||
| 28 |
4.13 (0.94) |
4.01 (0.86) |
-0.12 (-0.59 to 0.35) |
-3% |
||
| 30 |
4.24 (0.53) |
3.41 (0.53) |
-0.83 (-1.10 to -0.56) |
-20% |
||
| Placebo |
51 |
4.20 (1.60) |
4.30 (1.60) |
0.10 (-0.52 to 0.72) |
2% |
|
| 20 |
3.19 (0.87) |
2.70 (0.87) |
-0.49 (-1.03 to 0.05) |
-15% |
||
| Subtotal: 129 |
-0.38 (-0.83 to 0.07) |
0.10 |
||||
| Zhibituo |
104 |
3.70 (1.60) |
3.50 (1.40) |
-0.20 (-0.61 to 0.21) |
-5% |
0.34 |
| Placebo |
101 |
3.70 (1.20) |
3.70 (1.00) |
0.00 (-0.30 to 0.30) |
0% |
1.00 |
| HDL-C levels (mmol/L) |
||||||
| Cholestin |
42 |
1.29 (0.34) |
1.29 (0.36) |
0.00 (-0.15 to 0.15) |
0% |
1.00 |
| Placebo |
41 |
1.19 (0.26) |
1.19 (0.28) |
0.00 (-0.12 to 0.12) |
0% |
1.00 |
| 30 |
1.50 (0.46) |
1.67 (0.54) |
0.17 (-0.08 to 0.42) |
11% |
||
| 33 |
1.37 (0.21) |
1.16 (0.21) |
-0.21 (-0.31 to -0.11) |
-15% |
||
| Xuezhikang |
101 |
1.20 (0.40) |
1.40 (0.30) |
0.20 (0.10 to 0.30) |
17% |
|
| 30 |
1.20 (0.21) |
1.22 (0.21) |
0.02 (-0.09 to 0.13) |
2% |
||
| Subtotal: 194 |
0.04 (-0.17 to 0.24) |
0.73 |
||||
| 28 |
1.57 (0.69) |
1.53 (0.32) |
-0.04 (-0.32 to 0.24) |
-3% |
||
| 30 |
1.36 (0.24) |
1.13 (0.24) |
-0.23 (-0.35 to -0.11) |
-17% |
||
| 51 |
1.30 (0.40) |
1.30 (0.30) |
0.00 (-0.14 to 0.14) |
0% |
||
| Placebo |
20 |
1.22 (0.25) |
1.00 (0.25) |
-0.22 (-0.37 to -0.07) |
-18% |
|
| Subtotal: 129 |
-0.13 (-0.26 to -0.01) |
0.04 |
||||
| 13 |
0.89 (0.41) |
1.09 (0.41) |
0.20 (-0.12 to 0.52) |
22% |
||
| 30 |
1.08 (0.11) |
1.31 (0.17) |
0.23 (0.16 to 0.30) |
21% |
||
| Zhibituo |
104 |
0.85 (0.14) |
0.98 (0.26) |
0.13 (0.07 to 0.19) |
15% |
|
| Subtotal: 147 |
0.18 (0.10 to 0.26) |
< 0.0001 |
||||
| 13 |
0.92 (0.19) |
0.90 (0.17) |
-0.02 (-0.16 to 0.12) |
-2% |
||
| 30 |
0.99 (0.20) |
1.02 (0.28) |
0.03 (-0.09 to 0.15) |
3% |
||
| Placebo |
101 |
0.89 (0.13) |
0.80 (0.30) |
-0.09 (-0.15 to -0.03) |
-10% |
|
| Subtotal: 144 |
-0.04 (-0.12 to 0.03) |
0.26 |
||||
Liu et al. Chinese Medicine 2006 1:4 doi:10.1186/1749-8546-1-4 |
||||||